GlassScriptPhysician profile
Sumul N Raval
NPI 1376526673
$18,656.43
in general payments reported to CMS, 2019-2025
63 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $4,563 · 2021: $6,243 · 2022: $2,507 · 2023: $785 · 2024: $1,644 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,001 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,001.11 |
| Education | $319.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,465.85 | 2021-2025 | |
| Allergan, INC. | $4,594.80 | 2020-2021 | |
| Pfizer INC. | $485.42 | 2023-2025 | |
| Novocure INC. | $381.87 | 2019-2025 | Optune, Optune Gio |
| Biogen, INC. | $341.44 | 2019-2025 | Vumerity, Tysabri |
| Acadia Pharmaceuticals INC | $329.87 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $298.98 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $294.11 | 2019-2025 | |
| Eisai INC. | $277.16 | 2019-2025 | |
| Boston Scientific Corporation | $274.59 | 2020-2025 | General - Therapies, Watchman Flx |
| Ani Pharmaceuticals, INC. | $261.86 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $225.74 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Alexion Pharmaceuticals, INC. | $200.04 | 2019-2025 | Ultomiris, Soliris |
| Ucb, INC. | $165.84 | 2019-2025 | Briviact, Rystiggo |
| Neurocrine Biosciences, INC. | $110.13 | 2024-2025 | Ingrezza |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumul Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.